Last reviewed · How we verify
NCT03027024
Clinical Study to Investigate Visual Performance of IOL: FineVision HP
NA trial testing Implantation of IOL: PhysIOL POD F GF in Cataract in 22 participants. Completed in 22 October 2018.
22 October 2018
Quick facts
| Lead sponsor | Beaver-Visitec International, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 22 |
| Start date | 27 February 2017 |
| Primary completion | 22 October 2018 |
| Estimated completion | 22 October 2018 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Implantation of IOL: PhysIOL POD F GF
Conditions studied
- Cataract — all drugs for Cataract →
- Lens Opacity — all drugs for Lens Opacity →
Sponsor
Beaver-Visitec International, Inc.
Who can join
50 and older, any sex, with Cataract or Lens Opacity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, non-randomised, controlled, single-surgeon, single-center post-market clinical follow up study whereby patient undergoing routine cataract surgery will have bilateral implantation of a recently introduced TGA (Therapeutics Goods Authority, Australia) approved trifocal intraocular lens FineVision Evo (PhysIOL, Liège, Belgium). The primary and secondary effectiveness data for visual acuity, defocus curves, contrast sensitivity and any adverse events will be collected.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03027024
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cataract
Currently open trials in the same condition.
- NCT07301385 — Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety a · NA · recruiting
- NCT07462000 — Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract · NA · recruiting
- NCT06891092 — Vivinex Impress XY1-EM vs RayOne EMV · NA · recruiting
- NCT07218796 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
- NCT07218783 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
Other Beaver-Visitec International, Inc. trials
Trials by the same sponsor.
- NCT05875922 — Comparison of ISOPURE and EYHANCE (Switzerland) · NA · completed
- NCT04176965 — Investigation of the Safety and Effectiveness of a Trifocal IOL · NA · completed
- NCT05235139 — PMCF Study on Comparison of EDOF Lenses (Switzerland) · NA · completed
- NCT05255029 — Clinical Investigation of a Monofocal Toric Intra Ocular Lens (IOL) in Cataractous Eyes · NA · completed
- NCT04987216 — PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Europe (PHY2104) · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03027024 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beaver-Visitec International, Inc.
- Last refreshed: 6 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03027024.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing